Performed Clinical Trials
with NAC-GED-0507 - Acne
| STUDY | Tested Product Nr subjects exposed |
Study Design/Population | Treatment Duration |
|---|---|---|---|
| GED-0507-ACN-01-14 ACNE Phase 1 |
NAC-GED-0507 Gel 1% NAC-GED-0507 Gel 2% Active: 48 |
Open label clinical study to evaluate the dermal safety profile of 12-weeks topical administration of NAC-GED-0507 Gel, 1% and 2%, in patients with mild to moderate facial acne vulgaris Age: 14-30 years (males) and 18-30 years (females) |
12 weeks Once daily |
| NAC-GED-0507-ACN-02-17 ACNE Phase 1 |
NAC-GED-0507 Gel 5% Active: 25 |
An open label clinical study to evaluate the long-term dermal safety profile of 12-weeks topical administration of NAC-GED-0507 Gel 5% in patients with facial acne Age: 12-30 years (males) and 18-30 years (females) |
12 weeks Once daily |
| GED-0507-ACN-01-16 ACNE Phase 2a |
NAC-GED-0507 Gel 1% NAC-GED-0507 Gel 2% Placebo Gel (vehicle) Active: 100 Placebo: 47 |
Double-blind, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of NAC-GED-0507-Gel, 1% and 2%, applied once daily for 12 weeks in patients with mild to moderate facial acne vulgaris Age: 14-30 years (males) and 18-30 years (females) |
12 weeks Once daily |
| NAC-GED-0507-ACN-01-18 ACNE Phase 2b |
NAC-GED-0507 Gel 2% NAC-GED-0507 Gel 5% Placebo Gel (vehicle) Active: 300 Placebo: 150 |
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of NAC-GED-0507 gel, 2% and 5%, applied once daily for 12 weeks in patients with facial acne vulgaris Age 12-30 years |
12 weeks Once daily |
